PTGX in the 13F filings
Protagonist Therapeutics Inc · CUSIP 74366E102
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 20
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 9 listed it in both
- Shares listed
- 21,681,938
- combined, among listed positions
- Reported value
- $2.3bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 16 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,906,372.
Managers listing PTGX in Q1 2026
20 of 20 holders
Largest increases and reductions, by shares
Increases
- Invesco Ltdexisting position · 2,164,670 shares now+596,830
- Wellington Management Group LLPexisting position · 3,599,644 shares now+428,221
- Citadel Advisors LLCexisting position · 1,551,900 shares now+425,213
- T. Rowe Price Associates Incexisting position · 1,665,497 shares now+264,759
- Janus Henderson Group Ltdexisting position · 2,891,527 shares now+241,546
Reductions
- Marshall Wace LLPexisting position · 628,075 shares now-396,850
- Hudson Bay Capital Management LPexisting position · 3,760 shares now-105,855
- Jane Street Group LLCexisting position · 3,607 shares now-30,700
- Holocene Advisors LPexisting position · 209,916 shares now-103
New positions and exits
New (2)
Exited (6)
- Soros Fund Management LLCwas $8.7m
- Verition Fund Management LLCwas $2.3m
- Millennium Management LLCwas $1.5m
- Renaissance Technologies LLCwas $713k
- Tudor Investment Corpwas $674k
- Arrowstreet Capital LPwas $443k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2017 | 1 | $231k | n.a. | n.a. |
| Q2 2017 | 1 | $197k | n.a. | n.a. |
| Q3 2017 | 1 | $458k | n.a. | n.a. |
| Q4 2017 | 2 | $19m | n.a. | n.a. |
| Q1 2018 | 1 | $8.7m | n.a. | n.a. |
| Q2 2018 | 2 | $6.5m | n.a. | n.a. |
| Q3 2018 | 1 | $23m | n.a. | n.a. |
| Q4 2018 | 2 | $15m | n.a. | n.a. |
| Q1 2019 | 2 | $23m | n.a. | n.a. |
| Q2 2019 | 3 | $20m | n.a. | n.a. |
| Q3 2019 | 2 | $18m | n.a. | n.a. |
| Q4 2019 | 1 | $11m | n.a. | n.a. |
| Q1 2020 | 1 | $11m | n.a. | n.a. |
| Q2 2020 | 2 | $48m | n.a. | n.a. |
| Q3 2020 | 1 | $54m | n.a. | n.a. |
| Q4 2020 | 2 | $60m | n.a. | n.a. |
| Q1 2021 | 2 | $87m | n.a. | n.a. |
| Q2 2021 | 2 | $156m | n.a. | n.a. |
| Q3 2021 | 4 | $130m | n.a. | n.a. |
| Q4 2021 | 4 | $169m | n.a. | n.a. |
| Q1 2022 | 3 | $110m | n.a. | n.a. |
| Q2 2022 | 5 | $67m | n.a. | n.a. |
| Q3 2022 | 3 | $53m | n.a. | n.a. |
| Q4 2022 | 5 | $52m | n.a. | n.a. |
| Q1 2023 | 4 | $116m | n.a. | n.a. |
| Q2 2023 | 5 | $171m | n.a. | n.a. |
| Q3 2023 | 2 | $109m | n.a. | n.a. |
| Q4 2023 | 2 | $191m | 2 | 0 |
| Q1 2024 | 5 | $248m | 4 | 1 |
| Q2 2024 | 3 | $262m | 2 | 2 |
| Q3 2024 | 3 | $286m | 2 | 1 |
| Q4 2024 | 4 | $253m | 3 | 0 |
| Q1 2025 | 4 | $354m | 3 | 1 |
| Q2 2025 | 5 | $425m | 4 | 1 |
| Q3 2025 | 8 | $790m | 8 | 0 |
| Q4 2025 | 10 | $1.3bn | 14 | 14 |
| Q1 2026 | 9 | $1.8bn | 16 | 10 |
| Q2 2026 | 7 | $1.9bn | 14 | 10 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
PTGX and LLY →PTGX and JNJ →PTGX and VRTX →Choose a stock to compare with PTGX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own PTGX, latest filings →Back to the 13F Explorer →